ArticleInternational journal of molecular sciences2026
Inhibitory Mechanism of Bee Venom Against A431 Cutaneous Squamous Cell Carcinoma Cells Based on Label-Free Proteomics and Untargeted Metabolomics.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The incidence of cutaneous squamous cell carcinoma (cSCC) has been rising steadily in recent years, yet treatment options for advanced-stage patients remain limited. Bee venom (BV) possesses diverse biological activities including inhibiting tumor cell growth in various tumor models, but its underlying mechanism against cSCC A431 cells remains unclear. This study evaluated the antiproliferative effect of BV on A431 cells using the CCK-8 assay and explored its mechanism of action through label-free proteomics and untargeted metabolomics. BV inhibited A431 cell proliferation in a dose-dependent manner, with a half-maximal inhibitory concentration of 11.57 μg/mL. Proteomics analysis revealed that 118 differentially expressed proteins were mainly enriched in the p53 signaling pathway, mineral absorption, and base excision repair pathways. Metabolomics screening yielded 336 differentially expressed metabolites, primarily enriched in amino acid biosynthesis and metabolism. BV exerts its anti-A431 cell bioactivity potentially by synergistically regulating tumor-related signaling pathways, mineral homeostasis, and proteins involved in DNA repair processes, thereby disrupting amino acid biosynthesis and metabolism. But the transcriptomic data failed to confirm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.